Activity Description & Educational Objectives
In this activity, an expert in cystic fibrosis (CF) discusses existing and emerging agents aimed at improving lung function in this disease. Furthermore, optimal management of CF-related gastrointestinal complications is highlighted.
Upon completion of this activity, participants should be better able to:
- Summarize recent findings on emerging therapies with the potential to improve lung function and treat GI complications in cystic fibrosis (CF)
- Describe recent clinical trial data on emerging therapy for lung health maintenance in CF, including antibiotics and disease-modifying agents
- Develop an individualized plan to improve clinical outcomes associated with GI complications in patients with CF
This activity has been designed to meet the educational needs of pulmonologists, gastroenterologists, and other clinicians involved in managing patients with cystic fibrosis.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Release and Expiration Dates: February 05, 2013 - February 04, 2014
Time to Complete: 30 minutes
Faculty & Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, National Jewish Health has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Course Director and Interviewee
Stanley B. Fiel, MD, FACP, FCCP
Professor & Chairman of Medicine
Director Adult Cystic Fibrosis Center
Morristown Medical Center
Morristown, New Jersey
Stanley B. Fiel, MD, FACP, FCCP, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer Corporation; Boehringer Ingelheim; Mpex Pharmaceuticals, Inc.; Novartis Corporation; Pfizer Inc; and PTC Therapeutics.
Grant/Research Support from Boehringer Ingelheim; Cystic Fibrosis Foundation; Gilead; Novartis Corporation; Transave; and Vertex Pharmaceuticals Incorporated.
Speakers Bureau participant with Dey Pharma; Genentech, Inc.; Gilead; GlaxoSmithKline; Novartis Corporation; Pfizer Inc.
Bradley E. Chipps, MD
Capital Allergy & Respiratory Disease Center
Medical Director of Respiratory Therapy and the Cystic Fibrosis Center
Sutter Medical Center
Bradley E. Chipps, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca; Dey Pharma; Genentech, Inc.; GlaxoSmithKline; ISTA Pharmaceuticals, Inc; Merck & Co., Inc.; Novartis Corporation; SRxA; and Sunovion Pharmaceuticals Inc.
Speakers Bureau participant with AstraZeneca; Genentech, Inc.; GlaxoSmithKline; ISTA Pharmaceuticals, Inc; Merck & Co., Inc.; Novartis Corporation; and Sunovion Pharmaceuticals Inc.
Harold Nelson, MD
Professor of Medicine
Division of Allergy and Immunology
National Jewish Health and University of Colorado School of Medicine
Harold Nelson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Circassia and Merck & Co. Inc.
Grant/Research Support from Circassia; Lincoln Diagnostics, Inc.; National Institutes of Health (NIH); and Rigel.
Christopher Washburn, PhD
PVI, PeerView Institute for Medical Education
Christopher Washburn, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.
The National Jewish Health ("NJH") and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, "NJH Parties") shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.
By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.
Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of National Jewish Health and PVI, PeerView Institute for Medical Education. National Jewish Health is accredited by the ACCME to provide continuing medical education for physicians.
National Jewish Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by educational grants from Aptalis Pharma US, Inc. and Vertex Pharmaceuticals Incorporated.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.